Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium
Tweet this page

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Advertisement

Advertisement



Advertisement